Table 2.

The top two significant genes across five CRC relevant signalling pathways from the TCGA Legacy dataset. A Kaplan–Meier estimate and log-rank test were used to compute the association between patient event-free survival and gene expressions. The associated hazard ratio, 95% confidence interval, p-value, mafdr (estimate positive false discovery rate for multiple hypothesis testing), and standard error are apparent. “Patient” indicates the number of patients for which data were available. The last column, “significant”, indicates the number of significant genes out of the total number of genes for this pathway. The fold change and p-value cut-off used were 0.5 and 0.05, respectively.

Genes	Hazard Ratio	95% Confidence Interval	p-Value	mafdr	Standard Error	Patient	Significant
(1) WNT							53/119
DVL3	2.8158	(1.6159–4.9066)	2.58$\times {10}^{-4}$	1.37$\times {10}^{-2}$	0.2833	329
VANGL2	2.7692	(1.5039–5.0992)	1.08$\times {10}^{-3}$	1.40$\times {10}^{-2}$	0.3115	329
(2) PI3K-Akt							159/340
EFNA1	3.2860	(1.8496–5.8377)	4.96$\times {10}^{-5}$	9.92$\times {10}^{-5}$	0.2932	329
KRAS	0.2853	(0.1502–0.5418)	1.27$\times {10}^{-4}$	1.26$\times {10}^{-4}$	0.3272	329
(3) TP53							11/38
BCL2	0.4610	(0.2960–0.7179)	6.12$\times {10}^{-4}$	0.0012	0.2260	329
CDKN2A	1.8156	(1.1931–2.7629)	5.36$\times {10}^{-3}$	0.0054	0.2142	329
(4) MAPK							113/252
KRAS	0.2853	(0.1502–0.5418)	1.27$\times {10}^{-4}$	2.09$\times {10}^{-4}$	0.3272	329
CACNA1I	2.7685	(1.6159–4.7432)	2.10$\times {10}^{-4}$	2.09$\times {10}^{-4}$	0.2747	313
(5) TGF-Beta							53/135
TERT	2.8734	(1.6639–4.96201)	1.53$\times {10}^{-4}$	3.05$\times {10}^{-4}$	0.2787	328
TGFB1I1	2.2381	(1.3807–3.6281)	1.08$\times {10}^{-3}$	0.0011	0.2465	329